Sandra Isabelle Barros Alves - 28 Jan 2026 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Role
SVP, Finance and CAO
Signature
/s/ Steve Forte, Attorney-in-Fact
Issuer symbol
RPTX
Transactions as of
28 Jan 2026
Net transactions value
$0
Form type
4
Filing time
28 Jan 2026, 20:30:05 UTC
Previous filing
29 Apr 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Alves Sandra Isabelle Barros SVP, Finance and CAO C/O REPARE THERAPEUTICS INC., 7171 FREDERICK BANTING, BLD. 2, STE. 270, ST-LAURENT, QUEBEC, CANADA /s/ Steve Forte, Attorney-in-Fact 28 Jan 2026 0002065621

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPTX Common Shares Disposed to Issuer -31,622 -100% 0 28 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RPTX Employee Stock Option (right to buy) Disposed to Issuer $0 -26,000 -100% $0.000000 0 28 Jan 2026 Common Shares 26,000 $1.17 Direct F3
transaction RPTX Employee Stock Option (right to buy) Disposed to Issuer $0 -24,500 -100% $0.000000 0 28 Jan 2026 Common Shares 24,500 $1.07 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sandra Isabelle Barros Alves is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes 18,800 shares of common stock underlying restricted stock units that were cancelled pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share.
F2 Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.
F3 This option was cancelled pursuant to the Arrangement Agreement in exchange for (i) $2.20 less the applicable exercise price in respect of such option plus (ii) one CVR per share underlying such option.